Dupilumab elicits a favorable response in type-2 inflammatory comorbidities of severe atopic dermatitis

Eustachio Nettis; Lucia Masciopinto; Elisabetta Di Leo; Nicola De Candia; Marcello Albanesi; Danilo Di Bona; Nicola Quaranta; Luigi Macchia

doi:10.1186/s12948-021-00144-x

Clinical and Molecular Allergy (Jun 2021)

Dupilumab elicits a favorable response in type-2 inflammatory comorbidities of severe atopic dermatitis

Eustachio Nettis,
Lucia Masciopinto,
Elisabetta Di Leo,
Nicola De Candia,
Marcello Albanesi,
Danilo Di Bona,
Nicola Quaranta,
Luigi Macchia

Affiliations

Eustachio Nettis: Department of Emergency and Organ Transplantation, School of Allergology and Clinical Immunology, University of Bari Aldo Moro, Policlinico Di Bari
Lucia Masciopinto: Department of Emergency and Organ Transplantation, School of Allergology and Clinical Immunology, University of Bari Aldo Moro, Policlinico Di Bari
Elisabetta Di Leo: Section of Allergy and Clinical Immunology, Unit of Internal Medicine – “F. Miulli” Hospital, Acquaviva Delle Fonti
Nicola De Candia: Department of Neuroscience and Sensory Organs, Otolaryngology Unit, University of Bari Aldo Moro, Policlinico Di Bari
Marcello Albanesi: Department of Emergency and Organ Transplantation, School of Allergology and Clinical Immunology, University of Bari Aldo Moro, Policlinico Di Bari
Danilo Di Bona: Department of Emergency and Organ Transplantation, School of Allergology and Clinical Immunology, University of Bari Aldo Moro, Policlinico Di Bari
Nicola Quaranta: Department of Neuroscience and Sensory Organs, Otolaryngology Unit, University of Bari Aldo Moro, Policlinico Di Bari
Luigi Macchia: Department of Emergency and Organ Transplantation, School of Allergology and Clinical Immunology, University of Bari Aldo Moro, Policlinico Di Bari

DOI: https://doi.org/10.1186/s12948-021-00144-x
Journal volume & issue: Vol. 19, no. 1
pp. 1 – 4

Abstract

Read online

Abstract Background This case is the first report describing rapid, successful treatment of severe atopic dermatitis (AD) and comorbid type-2 inflammatory diseases in the same patient, with dupilumab treatment, with no side-effects. Case presentation We report on effects of dupilumab in a patient with severe AD, a long-standing history of a mild, perennial allergic rhino-conjunctivitis, moderate asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). Conclusions Patients suffering from AD, asthma, allergic rhinitis and CRSwNP may be eligible for dupilumab single treatment that is possibly advantageous also from the pharmaco-economic standpoint.

Published in Clinical and Molecular Allergy

ISSN: 1476-7961 (Online)
Publisher: BMC
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: https://clinicalmolecularallergy.biomedcentral.com

About the journal

Abstract

Keywords